NASDAQ:TECH

Bio-Techne (TECH) Stock Forecast, Price & News

$66.50

-0.65 (-0.97%)

(As of 10/3/2023 ET)

Compare

Today's Range: $65.93
▼
$67.29
50-Day Range: $66.50
▼
$84.98
52-Week Range: $65.77
▼
$90.63

Volume: 1.04 million shs
Average Volume: 871,691 shs
Market Capitalization: $10.52 billion

P/E Ratio: 37.73
Dividend Yield: 0.48%
Price Target: $101.58

Bio-Techne MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.78 Rating Score
Upside/Downside: 52.7% Upside
$101.58 Price Target
Short Interest: Bearish
2.17% of Shares Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -1.37
Upright™ Environmental Score
News Sentiment: 1.12
Based on 10 Articles This Week
Insider Trading: Selling Shares
$7.79 M Sold Last Quarter
Proj. Earnings Growth: 18.39%
From $1.74 to $2.06 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.09 out of 5 stars

Medical Sector

25th out of 965 stocks

Biological Products, Except Diagnostic Industry

2nd out of 157 stocks

3.4

Analyst's Opinion

Consensus Rating
Bio-Techne has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $101.58, Bio-Techne has a forecasted upside of 52.7% from its current price of $66.50.
Amount of Analyst Coverage
Bio-Techne has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.17% of the outstanding shares of Bio-Techne have been sold short.
Short Interest Ratio / Days to Cover
Bio-Techne has a short interest ratio ("days to cover") of 4.2.
Change versus previous month
Short interest in Bio-Techne has recently increased by 10.97%, indicating that investor sentiment is decreasing significantly.

1.7

Dividend Strength

Dividend Yield
Bio-Techne has a dividend yield of 0.48%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bio-Techne has only been increasing its dividend for 1 years.
Dividend Coverage
The dividend payout ratio of Bio-Techne is 18.16%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bio-Techne will have a dividend payout ratio of 15.53% next year. This indicates that Bio-Techne will be able to sustain or increase its dividend.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bio-Techne has received a 65.41% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antibodies", "Biochemical assay kits", and "Biochips" products. See details.
Environmental Sustainability
The Environmental Impact score for Bio-Techne is -1.37.

4.0

News and Social Media Coverage

News Sentiment
Bio-Techne has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Bio-Techne this week, compared to 5 articles on an average week.
Search Interest
17 people have searched for TECH on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
MarketBeat Follows
95 people have added Bio-Techne to their MarketBeat watchlist in the last 30 days. This is an increase of 1,257% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Techne insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,786,780.00 in company stock.
Percentage Held by Insiders
Only 4.10% of the stock of Bio-Techne is held by insiders.
Percentage Held by Institutions
94.64% of the stock of Bio-Techne is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Bio-Techne are expected to grow by 18.39% in the coming year, from $1.74 to $2.06 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Techne is 37.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.32.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Techne is 37.73, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 93.95.
Price to Earnings Growth Ratio
Bio-Techne has a PEG Ratio of 3.69. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bio-Techne has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bio-Techne (NASDAQ:TECH) Stock

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

TECH Price History

30 days | 90 days | 365 days | Advanced Chart

TECH Stock News Headlines

October 3, 2023 | finance.yahoo.com

3 Healthcare Stocks to Keep an Eye On

October 2, 2023 | americanbankingnews.com

Bio-Techne Co. (NASDAQ:TECH) Receives Average Recommendation of "Moderate Buy" from Analysts

October 4, 2023 | Edge On The Street (Ad)

The Strategic Gold Play You Haven't Heard About

Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.

October 1, 2023 | americanbankingnews.com

StockNews.com Downgrades Bio-Techne (NASDAQ:TECH) to Hold

September 28, 2023 | finance.yahoo.com

DR. JORDAN LASER AWARDED AMP MERITORIOUS SERVICE AWARD

September 27, 2023 | barrons.com

Bio-Techne Corp.

September 27, 2023 | finance.yahoo.com

SCIENTISTS AT CE PHARM CONFERENCE DESCRIBE HOW Maurice™ AND MauriceFlex™ SYSTEMS TRANSFORM THEIR PROTEIN ANALYSIS

September 26, 2023 | finance.yahoo.com

BIO-TECHNE INTEGRATES ITS MAURICE SYSTEM WITH THE THERMO SCIENTIFIC CHROMELEON CHROMATOGRAPHY DATA SYSTEM

October 4, 2023 | Wall Street Fundamentals (Ad)

Would Buffett Approve of This Growth Strategy?

Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.

September 25, 2023 | finance.yahoo.com

BIO-TECHNE ISSUES 2023 CORPORATE SUSTAINABILITY REPORT

September 19, 2023 | finance.yahoo.com

Cizzle and Bio-Techne Announce Completion of Evaluation Programme for Detection of CIZ1B Using ProteinSimple Branded Simple Western™ Platform

September 13, 2023 | msn.com

RBC Capital Reiterates Bio-Techne (TECH) Sector Perform Recommendation

September 3, 2023 | finance.yahoo.com

Does Bio-Techne (NASDAQ:TECH) Deserve A Spot On Your Watchlist?

August 28, 2023 | barrons.com

Most Stocks in S&P 500 Are Rising Monday

August 28, 2023 | msn.com

William Blair Initiates Coverage of Bio-Techne (TECH) with Outperform Recommendation

August 28, 2023 | finance.yahoo.com

Unveiling Bio-Techne (TECH)'s Value: Is It Really Priced Right? A Comprehensive Guide

August 28, 2023 | gurufocus.com

Unveiling the Investment Potential of Bio-Techne Corp (TECH): A Comprehensive Analysis of ...

August 28, 2023 | finance.yahoo.com

BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES

August 24, 2023 | finance.yahoo.com

BIO-TECHNE ANNOUNCES 2023 INVESTOR DAY AND WEBCAST

August 22, 2023 | seekingalpha.com

Bio-Techne Corporation: Not Paying The Premium Right Now

August 21, 2023 | finance.yahoo.com

Unveiling Bio-Techne Corp's Market Potential: A Comprehensive GF Score Analysis

August 19, 2023 | msn.com

Benchmark Reiterates Bio-Techne (TECH) Buy Recommendation

August 18, 2023 | gurufocus.com

Is Bio-Techne Corp (TECH) Modestly Undervalued?

August 17, 2023 | benzinga.com

Cell Isolation Market worth $8.2 billion | MarketsandMarkets

August 15, 2023 | finance.yahoo.com

BIO-TECHNE TO PRESENT AT THE UBS MEDTECH, TOOLS AND GENOMICS SUMMIT 2023

August 14, 2023 | markets.businessinsider.com

Bio-Techne, Akoya To End Co-development Of RNAscope For Use With PhenoCycler-Fusion System

August 14, 2023 | finance.yahoo.com

BIO-TECHNE ENDS COLLABORATION PROGRAM WITH AKOYA TO AUTOMATE RNASCOPE ON THE PHENOCYCLER FUSION

See More Headlines

Receive TECH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Techne and its competitors with MarketBeat's FREE daily newsletter.

TECH Company Calendar

Last Earnings: 8/08/2023
Ex-Dividend for 9/1 Dividend: 8/17/2023
Dividend Payable: 9/01/2023
Today: 10/04/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 6/30/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NASDAQ:TECH
CUSIP: 87837710
CIK: 842023
Web: www.bio-techne.com
Phone: (612) 379-8854
Fax: 612-656-4400
Employees: 3,050
Year Founded: 1981

Price Target and Rating

Average Stock Price Forecast: $101.58
High Stock Price Forecast: $120.00
Low Stock Price Forecast: $86.00
Forecasted Upside/Downside: +52.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.78
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.7625
Trailing P/E Ratio: 37.73
Forward P/E Ratio: 38.22
P/E Growth: 3.74
Net Income: $285.26 million
Net Margins: 25.10%
Pretax Margin: 29.79%
Return on Equity: 15.47%
Return on Assets: 11.56%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 4.84
Quick Ratio: 3.50

Sales & Book Value

Annual Sales: $1.14 billion
Price / Sales: 9.26
Cash Flow: $2.46 per share
Price / Cash Flow: 27.05
Book Value: $12.49 per share
Price / Book: 5.32

Miscellaneous

Outstanding Shares: 158,240,000
Free Float: 151,752,000
Market Cap: $10.52 billion
Optionable: Optionable
Beta: 1.23

Social Links

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Charles R. Kummeth (Age 63)
CEO, Pres & Director
Comp: $1.26M

Mr. James T. Hippel (Age 52)
Exec. VP of Fin. & CFO
Comp: $691.78k

Mr. Shane Bohnen (Age 48)
Sr. VP, Gen. Counsel & Corp. Sec.
Comp: $353.6k

Mr. Kim Kelderman (Age 56)
Pres of Diagnostics & Genomics
Comp: $845.71k

Mr. William A. Geist (Age 53)
Pres of Protein Sciences Segment
Comp: $533.67k

David Clair
Sr. Director of Investor Relations & Corp. Devel.

Mr. Gerry Andros
VP of Sales and Marketing

Mr. Robert M. Gavin (Age 55)
VP of Corp. Devel.

Ms. Brenda S. Everson
Sr. VP & Chief HR Officer

Mr. Luca Cicchetti
Managing Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TECH Stock - Frequently Asked Questions

Should I buy or sell Bio-Techne stock right now?: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Techne in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" TECH shares.
View TECH analyst ratings or view top-rated stocks.
What is Bio-Techne's stock price forecast for 2023?: 9 analysts have issued 12 month price targets for Bio-Techne's stock. Their TECH share price forecasts range from $86.00 to $120.00. On average, they anticipate the company's share price to reach $101.58 in the next year. This suggests a possible upside of 52.7% from the stock's current price.
View analysts price targets for TECH or view top-rated stocks among Wall Street analysts.
How have TECH shares performed in 2023?: Bio-Techne's stock was trading at $82.88 on January 1st, 2023. Since then, TECH stock has decreased by 19.8% and is now trading at $66.50.
View the best growth stocks for 2023 here.
When is Bio-Techne's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our TECH earnings forecast.
How were Bio-Techne's earnings last quarter?: Bio-Techne Co. (NASDAQ:TECH) issued its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported $0.56 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.07. The biotechnology company earned $301.32 million during the quarter, compared to analysts' expectations of $304.71 million. Bio-Techne had a net margin of 25.10% and a trailing twelve-month return on equity of 15.47%.
How often does Bio-Techne pay dividends? What is the dividend yield for Bio-Techne?: Bio-Techne announced a quarterly dividend on Tuesday, August 8th. Stockholders of record on Friday, August 18th will be paid a dividend of $0.08 per share on Friday, September 1st. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.48%. The ex-dividend date of this dividend is Thursday, August 17th.
Read our dividend analysis for TECH.
What ETFs hold Bio-Techne's stock?: ETFs with the largest weight of Bio-Techne (NASDAQ:TECH) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), American Century Mid Cap Growth Impact (MID), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), BlackRock Future Innovators ETF (BFTR), Putnam BioRevolution ETF (SYNB), Fidelity Disruptive Medicine ETF (FMED) and Harbor Health Care ETF (MEDI).
Is Bio-Techne a good dividend stock?: Bio-Techne (NASDAQ:TECH) pays an annual dividend of $0.32 per share and currently has a dividend yield of 0.47%. The company does not yet have a strong track record of dividend growth. The dividend payout ratio is 18.16%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, TECH will have a dividend payout ratio of 15.53% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for TECH.

When did Bio-Techne's stock split?: Bio-Techne shares split on Wednesday, November 30th 2022. The 4-1 split was announced on Tuesday, November 1st 2022. The newly issued shares were issued to shareholders after the market closes on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.
What is Charles Kummeth's approval rating as Bio-Techne's CEO?: 95 employees have rated Bio-Techne Chief Executive Officer Charles Kummeth on Glassdoor.com. Charles Kummeth has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Bio-Techne own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Techne investors own include Paychex (PAYX), Gilead Sciences (gild), NVIDIA (NVDA), AbbVie (ABBV), Amgen (AMGN), Abbott Laboratories (ABT), Cisco Systems (CSCO), Johnson & Johnson (JNJ), AT&T (T) and Boeing (BA).
What is Bio-Techne's stock symbol?: Bio-Techne trades on the NASDAQ under the ticker symbol "TECH."
How do I buy shares of Bio-Techne?: Shares of TECH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bio-Techne's stock price today?: One share of TECH stock can currently be purchased for approximately $66.50.
How much money does Bio-Techne make?: Bio-Techne (NASDAQ:TECH) has a market capitalization of $10.52 billion and generates $1.14 billion in revenue each year. The biotechnology company earns $285.26 million in net income (profit) each year or $1.7625 on an earnings per share basis.
How many employees does Bio-Techne have?: The company employs 3,050 workers across the globe.
Does Bio-Techne have any subsidiaries?: The following companies are subsidiares of Bio-Techne: Advanced Cell Diagnostics, Advanced Cell Diagnostics Inc., B-MoGen Biotechnologies Inc., Bio-Techne China Co. Ltd, Bio-Techne Ltd., Bionostics Inc., Cliniqa, CyVek, Exosome Diagnostics, Exosome Diagnostics Inc., MoGen Biotechnologies, Novus Biologicals, Novus Biologicals LLC, ProteinSimple, ProteinSimple Ltd., QT Holdings Corporation, Quad Technologies, Research and Diagnostic Systems Inc., Shanghai PrimeGene Bio-Tech Co. Ltd., Space Import-Export Srl, Tocris Cookson Limited, and Zephyrus Biosciences.
Read More
How can I contact Bio-Techne?: Bio-Techne's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The official website for the company is www.bio-techne.com. The biotechnology company can be reached via phone at (612) 379-8854, via email at ir@bio-techne.com, or via fax at 612-656-4400.

This page (NASDAQ:TECH) was last updated on 10/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial